Results 71 to 80 of about 27,519 (289)
Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration
Cell Communication and Signaling, 2018 Background Medulloblastoma (MB) is the most common malignant brain tumor in children. Current problems in the clinic include metastasis, recurrence, and treatment-related sequelae that highlight the need for targeted therapies.
Keri Callegari +3 more
doaj +1 more source
Diabetology & Metabolic Syndrome, 2022 Objective Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. Histone lysine-specific demethylase 1 (LSD1) is a flavin-containing amino oxidase that can repress or activate transcription.
Lina Dong, Lei Yu, Jin Zhong
doaj +1 more source
Application of Small Epigenetic Modulators in Pediatric Medulloblastoma [PDF]
, 2018 Medulloblastoma is one of the most frequent among pediatric brain tumors, and it has been classified in various subgroups. Some of them already benefit from quite good therapeutic options, whereas others urgently need novel therapeutic approaches ...
Annalisa Romanelli +8 more
core +2 more sources
Epigenetic regulation of LSD1 during mammary carcinogenesis [PDF]
Molecular & Cellular Oncology, 2014 Inheritable epigenetic regulation is integral to the dynamic control of gene expression under different stimuli for cellular homeostasis and disease progression. Histone methylation is a common and important type of chromatin modification. LSD1, the first known histone lysine-specific demethylase, operates as a key component of several corepressor ...
Wu, Yadi, Zhou, Binhua P
openaire +2 more sources
The long non-coding RNA Kcnq1ot1 controls maternal p57 expression in muscle cells by promoting H3K27me3 accumulation to an intragenic MyoD-binding region [PDF]
, 2019 BACKGROUND: The cell-cycle inhibitor p57kip2 plays a critical role in mammalian development by coordinating cell proliferation and differentiation in many cell types.
Andresini, Oriella +5 more
core +4 more sources
Discovery of novel dual-target inhibitors of LSD1/EGFR for non-small cell lung cancer therapy
Acta Pharmacologica SinicaHistone lysine-specific demethylase 1 (LSD1) is overexpressed in various solid and hematological tumors, suggesting its potential as a therapeutic target, but there are currently no LSD1 inhibitors available on the market.
Yu Wei +6 more
semanticscholar +1 more source
Current Oncology, 2023 Tumor evolution to evade immune surveillance is a hallmark of carcinogenesis, and the modulation of tumor immunogenicity has been a challenge to present therapeutic responses in immunotherapies alone for numerous cancers.
Dong Yeul Lee +2 more
semanticscholar +1 more source
Dual inhibitors of LSD1 and spermine oxidase [PDF]
MedChemComm, 2019 Dual inhibitors of LSD1 and SMOX, with no activity against N1-acetylpolyamine oxidase (PAOX).
Steven Holshouser +8 more
openaire +2 more sources
Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. [PDF]
, 2018 Hepatocellular carcinoma (HCC), is one of the most frequent human cancer and is characterized by a high mortality rate. The aggressiveness appears strictly related to the liver pathological background on which cancer develops.
Amicone, Laura, Marchetti, Alessandra
core +1 more source
Clinical Cancer Research, 2022 PURPOSE The addition of immune checkpoint blockade (ICB) to platinum/etoposide chemotherapy changed the standard of care for small cell lung cancer (SCLC) treatment.
Joseph B Hiatt +13 more
semanticscholar +1 more source